多发性骨髓瘤靶向给药系统的最新进展
Recent advances in targeted drug delivery systems for multiple myeloma.
作者信息
Pant Ashruti, Laliwala Aayushi, Holstein Sarah A, Mohs Aaron M
机构信息
Department of Pharmaceutical Sciences, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 505 S 45 St, Omaha, NE 68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 505 S 45 St, Omaha, NE 68198, USA.
Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 505 S 45 St, Omaha, NE 68198, USA; Department of Internal Medicine, University of Nebraska Medical Center, 505 S 45 St, Omaha, NE 68198, USA.
出版信息
J Control Release. 2024 Dec;376:215-230. doi: 10.1016/j.jconrel.2024.10.003. Epub 2024 Oct 12.
Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM.
尽管在治疗方面取得了重大进展，但多发性骨髓瘤（MM）仍然是一种具有挑战性的、无法治愈的血液系统恶性肿瘤。传统化疗和目前可用的抗MM药物的疗效部分受到其副作用的限制，这限制了它们的治疗潜力。纳米治疗是癌症治疗的一个新兴领域，它可以克服现有抗癌药物的生物和化学屏障。本文综述了基于纳米颗粒和免疫疗法的药物递送系统在MM治疗方面的最新进展。它进一步深入探讨了靶向策略、药物控释机制以及与MM治疗药物递送系统开发相关的挑战。
Zotero 插件